October 2, 2026, 12:29 pm | Read time: 5 minutes
Chronic inflammation may play a significant role in the development of cardiovascular diseases. One possible indicator of this is C-reactive protein (CRP), whose concentration in the blood can increase during inflammatory processes. Doctors typically test this value in the lab when they suspect hidden inflammation in a patient’s body. Researchers have now investigated whether persistently elevated CRP levels are also associated with the later onset of heart failure.
Higher Risk of Heart Failure with Elevated CRP
People with persistently elevated CRP levels developed heart failure more frequently than those with lower levels. Over a ten-year period, 10.8 percent were affected, compared to 8.3 percent in the comparison group. The rate of new heart failure diagnoses was about one-third higher with elevated CRP during follow-up.
How the Study Was Conducted
According to a study cited by the authors, more than 64 million people worldwide live with heart failure.1 Previous research suggests that chronic, low-grade inflammation may contribute to its development. However, it was unclear to what extent persistently elevated CRP levels are associated with later heart failure.
An international research team led by CHRU de Nancy and the Université de Lorraine in France investigated whether persistently elevated CRP levels are linked to a higher risk of heart failure. They analyzed electronic health data from 64,743 adults aged 40 to 80. All had at least two cardiovascular risk factors such as high blood pressure, type 2 diabetes, lipid metabolism disorders, or smoking, and none had heart failure at the start.2
Each participant had at least two CRP measurements. Values consistently measured between 0.1 and three milligrams per liter were considered low, while values between 3.1 and ten milligrams per liter were considered elevated. Higher values were excluded to limit the potential influence of acute inflammation.
The researchers statistically matched the groups based on numerous characteristics, including age, gender, body mass index, and existing conditions. Each group then included 19,547 participants. The median follow-up period was 3.9 years.
Further Findings on Heart Failure and Mortality
During the follow-up, a total of 1,580 new cases of heart failure were documented. The difference between people with elevated and low CRP was evident after just one year: At that point, the calculated frequency was 1.4 percent and 0.9 percent. The absolute difference between the groups increased over time.
Mortality also showed a difference: In the group with persistently elevated CRP, 7.7 percent of participants died, compared to 4.3 percent in the group with lower values. When researchers considered deaths and newly developed heart failure together, the proportions were 16.3 and 11.5 percent.
The association was also evident in the two forms of heart failure studied. This was true for patients whose hearts pump less blood than normal into the body, as well as for those whose pumping capacity is largely preserved. Further analyses with different time frames and CRP thresholds yielded similar results.
Association Mainly in People Without Severe Obesity
Interesting differences also emerged regarding body weight. Among participants without severe obesity, persistently elevated CRP was associated with a significantly higher risk of heart failure. In participants with obesity, however, no clear association was found. Researchers suspect that in obesity, other factors already strain the heart, making the CRP level less influential.
Xanthelasmas: What the Yellow Deposits Can Reveal About Your Heart
This Diet Could Support Heart Health
Study Assessment
A strength of the study is the large data set with participants from multiple countries. Researchers only included individuals with at least two similar CRP measurements to reduce the influence of short-term inflammation. Additionally, the groups were made as statistically comparable as possible.
However, since existing health data were evaluated, the study cannot prove cause and effect. Unrecorded factors such as infections, comorbidities, or differences in medical care could have influenced the results. Since all participants already had an increased cardiovascular risk, the results cannot be easily generalized to the broader population.
Further uncertainties arise from the data itself: Heart failure was recorded via diagnosis codes, the intervals and courses of CRP measurements were unknown, and different CRP testing methods could not be distinguished. Deaths as a competing risk could also not be fully accounted for statistically.
Persistently elevated CRP levels could, however, provide additional insights into the long-term risk of heart failure. Whether inflammation itself contributes to this or elevated CRP merely reflects other risk factors remains open.
Several authors disclosed financial relationships with pharmaceutical or medical technology companies, which, according to the publication, were unrelated to the study.
What Other Studies Show on This Topic
A Dutch study with around 8,000 cardiovascular patients reached a similar conclusion in 2023: Over nearly ten years, people with the highest CRP levels had more than double the risk of being hospitalized for heart failure compared to those with the lowest levels.3
Whether the risk can be reduced by specifically dampening inflammation is questionable. The anti-inflammatory drug Ziltivekimab significantly lowered CRP levels in a large study but did not reduce the risk of major cardiovascular events.4 Two other studies on patients with heart failure were prematurely terminated in September 2026 because no benefit was expected.5 This suggests that elevated CRP is at least partly a warning signal and not solely the cause.